IP Library Granted Patent US 10,736,859
Granted Patent B2
US 10,736,859 · App. 16/429,852 · Granted Aug 11, 2020

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

Inventors: Marino Nebuloni (Rho, IT); Patrizia Colombo (Trezzano sul Naviglio, IT)
Assignee: Tonix Pharma Holdings Limited
A61K31/135A61K9/145A61K9/1623A61K9/1688A61K9/1694A61K31/047A61K31/137A61K47/02A61K47/10A61K47/12A61K47/26A61K31/55
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,736,859
App. No.
16/429,852
Granted
Aug 11, 2020
Kind
B2
Abstract

The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.

Claims (9)

1. A method of making a pharmaceutical composition comprising a eutectic of mannitol and Amitriptyline HCl, wherein the eutectic comprises 75%±2% by weight Amitriptyline HCl and 25%±2% by weight mannitol, comprising mixing Amitriptyline HCl and mannitol or milling Amitriptyline HCl and mannitol.

2. The method of claim 1 , comprising milling Amitriptyline HCl and mannitol.

3. The method of claim 2 , wherein, the Amitriptyline HCl and mannitol are milled in a high shear granulator.

4. The method of claim 1 , comprising mixing Amitriptyline HCl and mannitol.

5. The method of claim 4 , wherein the Amitriptyline HCl and mannitol are mixed via compression.

6. The method of claim 5 , wherein the Amitriptyline HCl and mannitol are compressed via roller compaction.

7. The method of claim 1 , wherein the Amitriptyline HCl is micronized Amitriptyline HCl.

8. The method of claim 1 , further comprising the step of adding a basifying agent to the pharmaceutical composition.

9. The method of claim 8 , wherein the basifying agent is K 2 HPO 4 , Na 2 HPO 4 , or anhydrous trisodium citrate.

Assignments (5)
NOVATION AGREEMENT Recorded Jul 8, 2024
From: TONIX PHARMA HOLDINGS LIMITED
To: TONIX PHARMA LIMITED
Reel/Frame 068217/0592 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2020
From: TONIX PHARMACEUTICALS, INC.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 052010/0959 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2019
From: NEBULONI, MARINO; COLOMBO, PATRIZIA
To: REDOX SRL
Reel/Frame 049350/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2019
From: REDOX SRL
To: TONIX PHARMACEUTICALS, INC.
Reel/Frame 049350/0090 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2019
From: TONIX PHARMACEUTICALS, INC.
To: TONIX PHARMA HOLDINGS LIMITED
Reel/Frame 049350/0097 →
Continuity (5)
Division 15941484 · Mar 30, 2018
Continuation 15459093 · Mar 15, 2017
Continuation 14214433 · Mar 14, 2014
Provisional Application 61792757 · Mar 15, 2013
Related Publication 20190282517A1 · Sep 19, 2019